Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2007

View Archived Issues

Zevalin meets primary endpoint in follicular non-Hodgkin's lymphoma trial

Plasmid-mediated delivery of IGF-1 gene useful in mouse model of ALS

GSK and Oncomed form strategic alliance to develop cancer stem cell antibodies

Weight loss seen with taranabant in obese subjects

KW-2449 safe and well tolerated in phase I study in hematologic malignancies

Platelet counts, safety assessed in phase I trial of LGD-4665 in healthy males

Responses seen in immune thrombocytopenic purpura patients given R-788

Genesis Bioventures changes name to Abviva

Reckitt Benckiser acquires Adams Respiratory for approximately USD 2.3 billion

Recent patents disclose novel agents for obesity and disorders of lipoprotein metabolism

Gene Logic will be renamed Ore Pharmaceuticals

Bristol-Myers and Gilead enter agreement to commercialize Atripla in Europe

TorreyPines Therapeutics reports positive results from phase I clinical trial of NGX-426

Novel immunosuppressant agents disclosed in recent Actelion patent

Novel therapeutic agents for glaucoma reported in recent Allergan patents

UCB reports positive results from phase III trial of Vimpat for diabetic neuropathic pain

Panacos reports positive results from 350 mg cohort of phase IIb study of bevirimat

Avax reports positive results from phase I/II study of MVax for stage 3 and 4 melanoma

SIRT1 activators show therapeutic potential in animal models of type 2 diabetes

Orexigen initiates phase III trial of Contrave for obesity

Data Safety Monitoring Board recommends continuation of MAESTRO-03 trial of MBP-8298

Roche files IND application with FDA for Genmab antibody for asthma

FDA accepts EntreMed's IND application for Panzem for rheumatoid arthritis

Vivus initiates EQUATE phase III trial of Qnexa in obese patients with co-morbidities

FDA accepts for filing two sNDA for Neupro for restless legs syndrome and PD

FDA deems Neurocrine's NDA for indiplon approvable pending additional safety and efficacy data

FDA approves BioMarin therapy for PKU

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...